Pain Therapeutics Announces Feedback From Recent Meeting With FDA On REMOXY To Resolve Disagreements With FDA; FDA Denied Making Errors Or Material Mistakes During Advisory Committee Meeting, Co. Says It Is No Closer To Product Approval
Benzinga Newsdesk